Grand Pharmaceutical Group Limited (HK:0512) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Grand Pharmaceutical Group Limited announced the completion of patient enrollment in their Phase II clinical study of STC3141, a promising drug for treating sepsis. This milestone could accelerate the global development of the drug, which has shown positive safety and efficacy results in previous studies for severe diseases like ARDS and severe COVID-19. Investors should note the potential for future advancements in Grand Pharmaceutical’s innovative treatment portfolio.
For further insights into HK:0512 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue